Literature DB >> 24904182

Association between nonalcoholic fatty liver disease and carotid artery inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography.

Seung Hwan Moon1, Tae Soo Noh1, Young Seok Cho1, Seon Pyo Hong1, Seung Hyup Hyun1, Joon Young Choi1, Byung-Tae Kim1, Kyung-Han Lee2.   

Abstract

We assessed the association between nonalcoholic fatty liver disease (NAFLD) and carotid artery inflammation measured by (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography. Participants were 755 consecutive otherwise healthy adult males who underwent a general health screening program. Carotid FDG uptake, represented as maximum target-to-background ratio, was increased with mild (n = 237; 1.61 ± 0.14; P = .033) and moderate NAFLD (n = 145; 1.63 ± 0.16; P = .005) compared with controls (n = 373; 1.58 ± 0.15). In patients aged >50 years, moderate NAFLD was the only independent risk factor for high carotid FDG uptake (odds ratio, 2.12; 95% confidence interval, 1.10-4.07; P = .001). Apparently healthy adult males with NAFLD have elevated carotid FDG uptake as well as increased carotid intima-media thickness, suggesting that they may be at an increased risk of having inflammatory atherosclerotic plaques in the carotid arteries.
© The Author(s) 2014.

Entities:  

Keywords:  FDG; PET/CT; atherosclerosis; carotid artery; nonalcoholic fatty liver disease

Mesh:

Substances:

Year:  2014        PMID: 24904182     DOI: 10.1177/0003319714537872

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  7 in total

1.  Non-alcoholic fatty liver disease: a pandemic disease with multisystem burden.

Authors:  Somaya Albhaisi; Danny Issa; Naim Alkhouri
Journal:  Hepatobiliary Surg Nutr       Date:  2018-10       Impact factor: 7.293

2.  Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals.

Authors:  Ansel Shao Pin Tang; Kai En Chan; Jingxuan Quek; Jieling Xiao; Phoebe Tay; Margaret Teng; Keng Siang Lee; Snow Yunni Lin; May Zin Myint; Benjamin Tan; Vijay K Sharma; Darren Jun Hao Tan; Wen Hui Lim; Apichat Kaewdech; Daniel Huang; Nicholas Ws Chew; Mohammad Shadab Siddiqui; Arun J Sanyal; Mark Muthiah; Cheng Han Ng
Journal:  Clin Mol Hepatol       Date:  2022-03-02

Review 3.  NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms?

Authors:  Cristiane A Villela-Nogueira; Nathalie C Leite; Claudia R L Cardoso; Gil F Salles
Journal:  Int J Mol Sci       Date:  2016-04-20       Impact factor: 5.923

Review 4.  Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets.

Authors:  Feliciano Chanana Paquissi
Journal:  Front Immunol       Date:  2016-11-11       Impact factor: 7.561

Review 5.  Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge.

Authors:  Justin A Steggerda; Krishnaraj Mahendraraj; Tsuyoshi Todo; Mazen Noureddin
Journal:  World J Gastroenterol       Date:  2020-07-28       Impact factor: 5.742

6.  Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume.

Authors:  Robin D Abeles; Benjamin H Mullish; Roberta Forlano; Torben Kimhofer; Maciej Adler; Alexandros Tzallas; Nikolaos Giannakeas; Michael Yee; Jamil Mayet; Robert D Goldin; Mark R Thursz; Pinelopi Manousou
Journal:  Aliment Pharmacol Ther       Date:  2019-03-05       Impact factor: 8.171

Review 7.  Dysregulated lipid metabolism links NAFLD to cardiovascular disease.

Authors:  Audrey Deprince; Joel T Haas; Bart Staels
Journal:  Mol Metab       Date:  2020-10-01       Impact factor: 8.568

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.